United States· US:23594-101_4cd73883-efb6-9773-e063-6394a90a8285
Karbinal
A carbinoxamine product containing carbinoxamine maleate, registered in United States by Aytu Therapeutics, LLC.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- CARBINOXAMINE MALEATE
- Manufacturer
- Aytu Therapeutics, LLC
- Country
- United States (US)
- ATC code
- R06AA08
- ATC class
- Carbinoxamine
- Defined daily dose
- 16 mg, O
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 4
- ndc1123594101012 BOTTLE, PLASTIC in 1 CARTON (23594-101-01) / 30 mL in 1 BOTTLE, PLASTIC
- ndc112359410105480 mL in 1 BOTTLE, PLASTIC (23594-101-05)
- ndc1123594-101-01
- ndc1123594-101-05
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
320 interactions on record for carbinoxamine.
Graded by severity as the source publishes them — 9 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Carbinoxamine · interactions on record
320 records
- 9 severe
- 309 moderate
- 2 minor
Most severe, free to view
- Potassium chlorideA12BA01severe
- Potassium citrateA12BA02severe
- Potassium chlorideB05XA01severe
- Sodium oxybateN01AX11severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under R06AA08
Carbinoxamine, as other registers publish it.
- United StatesCarbinoxamine MaleateTRIPOINT THERAPEUTICS, LLC
- United StatesCarbinoxamine MaleateGenus Lifesciences Inc.
- United StatesCarbinoxamine MaleateBiocomp Pharma, Inc.
- United StatesCarbinoxamine MaleateBluCrest Pharmaceuticals, LLC
- United StatesCarbinoxamine MaleateGenus Lifesciences Inc.
- United StatesCARBINOXAMINE MALEATELeading Pharma, LLC
- United StatesCarbinoxamine Maleate Extended-Release Oral SuspensionNeos Therapeutics, LP
- United StatesCARBZAHIPG Pharmaceuticals, inc.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/5a534d10-8324-40f3-bf72-d2c8eb23c4e2 GET /v1/drugs/5a534d10-8324-40f3-bf72-d2c8eb23c4e2?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": "4",
"substance": "CARBINOXAMINE MALEATE",
"productndc": "23594-101",
"dosage_form": "SUSPENSION, EXTENDED RELEASE",
"dea_schedule": null,
"strength_unit": "mg/5mL",
"application_number": "NDA022556",
"marketing_category": "NDA"
}See everything about carbinoxamine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.